Previous 10 | Next 10 |
home / stock / vphif / vphif news
VALEO PHARMA ANNOUNCES NEW BOARD APPOINTMENTS Canada NewsWire MONTREAL , June 22, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced that Ms. Tamara...
(NewsDirect) Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has once again seen record numbers as it unveils its second-quarter financials. The numbers include the 6th consecutive quarter of revenue growth at $13.6 million, up 184% over 2Q 2022...
VALEO PHARMA REPORTS RECORD SECOND QUARTER REVENUES Canada NewsWire Sixth consecutive quarter of revenue growth at $13.6 million in Q2-23, up 184% over Q2-22. Sixth consecutive quarter of adjusted EBITDA loss reduction at $1.7 million , a 53% improvement over...
VALEO PHARMA TO HOST SECOND QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST Canada NewsWire MONTREAL , June 7, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announ...
(NewsDirect) Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share guidance for the company’s second-quarter that reveal it is heading for the sixth straight quarter of record revenue. The company said it expects 2Q revenue to exceed $13.5 million while its...
2023-05-25 07:33:05 ET Canadian pharmaceutical company Valeo Pharma ( OTCQB:VPHIF ) expects Q2 revenues to exceed $13.5M vs. consensus of $10.47M, representing a sixth consecutive quarter of revenue growth and a quarterly record. Adjusted EBITDA loss to drop below $2.0M,...
VALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023 Canada NewsWire Q2-23 revenues to exceed $13.5 million Q2-23 adjusted EBITDA loss to decrease below $2.0 million Q2-23 operating expenses to remain in line with pri...
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS Canada NewsWire MONTREAL , April 28, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) (" Valeo " or the " Company "), a Canadian pharmaceuti...
VALEO PHARMA TO PRESENT AT THE 2023 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE VALEO PHARMA TO PRESENT AT THE 2023 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE Canada NewsWire MONTREAL , April 19, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VP...
(NewsDirect) Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company had a record quarter in the three months to January 31, 2023, with revenue of $13.2 million, up 210% over 1Q 2022. Saviuk tells Proactive this marks the 5th consecutive quarter of grow...
News, Short Squeeze, Breakout and More Instantly...
VALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE Canada NewsWire MONTREAL , June 18, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical compan...
(NewsDirect) Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the second quarter, which saw record-breaking revenue for the period. The company reported revenues of $14.1 million for Q2, an increase from the $13.6 million rec...
VALEO PHARMA ANNOUNCES RESTRUCTURING OF COMMERCIAL FIELD OPERATIONS TO SUPPORT PATH TO PROFITABILITY Canada NewsWire Changes to respiratory business unit to generate more than $5 million in annual savings Follows previously announced cost saving measures exce...